BioSpace News Archive

Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.

Coeptis Therapeutics Holdings, Inc. today announced that Dave Mehalick , President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on Wednesday, December 6th.

Acino today announced that it has completed the acquisition of M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association.

Panbela Therapeutics, Inc today announces the publication of preclinical data from studies of ivospemin (also known as SBP-101) and eflornithine (also known as CPP-1X or DFMO) research in multiple myeloma (cell lines).

On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.

Anitoa Systems, LLC, a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing, announced worldwide availability of its all-in-one swine flu test solution for live stocks.

Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate.

Centene Corporation (NYSE: CNC) (“the Company”) today announced that it will host an investor day on Tuesday, December 12, 2023.

Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1.